C.M. Bidwell & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.46K | Hold |
10
| – | – | ﹤0.01% | 336 |
|
|
2025
Q4 | $4.53K | Hold |
10
| – | – | ﹤0.01% | 339 |
|
|
2025
Q3 | $3.92K | Hold |
10
| – | – | ﹤0.01% | 363 |
|
|
2025
Q2 | $4.45K | Hold |
10
| – | – | ﹤0.01% | 330 |
|
|
2025
Q1 | $4.85K | Hold |
10
| – | – | ﹤0.01% | 311 |
|
|
2024
Q4 | $4.03K | Hold |
10
| – | – | ﹤0.01% | 363 |
|
|
2024
Q3 | $4.65K | Hold |
10
| – | – | ﹤0.01% | 336 |
|
|
2024
Q2 | $4.69K | Hold |
10
| – | – | ﹤0.01% | 327 |
|
|
2024
Q1 | $4.18K | Sell |
10
-946
| -99% | -$400K | ﹤0.01% | 337 |
|
|
2023
Q4 | $389K | Buy |
956
+7
| +0.7% | +$2.59K | 0.29% | 66 |
|
|
2023
Q3 | $330K | Sell |
949
-21
| -2% | -$7.34K | 0.25% | 65 |
|
|
2023
Q2 | $341K | Buy |
970
+675
| +229% | +$227K | 0.25% | 70 |
|
|
2023
Q1 | $92.9K | Hold |
295
| – | – | 0.07% | 241 |
|
|
2022
Q4 | $85.2K | Hold |
295
| – | – | 0.07% | 247 |
|
|
2022
Q3 | $85K | Buy |
295
+285
| +2,850% | +$82K | 0.07% | 234 |
|
|
2022
Q2 | $3K | Hold |
10
| – | – | ﹤0.01% | 422 |
|
|
2022
Q1 | $3K | Hold |
10
| – | – | ﹤0.01% | 463 |
|
|
2021
Q4 | $2K | Hold |
10
| – | – | ﹤0.01% | 525 |
|
|
2021
Q3 | $2K | Hold |
10
| – | – | ﹤0.01% | 524 |
|
|
2021
Q2 | $2K | Hold |
10
| – | – | ﹤0.01% | 524 |
|
|
2021
Q1 | $2K | Sell |
10
-671
| -99% | -$147K | ﹤0.01% | 488 |
|
|
2020
Q4 | $161K | Sell |
681
-39
| -5% | -$8.95K | 0.13% | 155 |
|
|
2020
Q3 | $196K | Sell |
720
-889
| -55% | -$245K | 0.18% | 116 |
|
|
2020
Q2 | $467K | Sell |
1,609
-1,091
| -40% | -$296K | 0.43% | 39 |
|
|
2020
Q1 | $642K | Buy |
2,700
+1,367
| +103% | +$314K | 0.68% | 29 |
|
|
2019
Q4 | $292K | Buy |
1,333
+25
| +2% | +$5.06K | 0.26% | 85 |
|
|
2019
Q3 | $222K | Buy |
1,308
+1,298
| +12,980% | +$230K | 0.22% | 116 |
|
|
2019
Q2 | $2K | Hold |
10
| – | – | ﹤0.01% | 372 |
|
|
2019
Q1 | $2K | Hold |
10
| – | – | ﹤0.01% | 370 |
|
|
2018
Q4 | $2K | Hold |
10
| – | – | ﹤0.01% | 364 |
|
|
2018
Q3 | $2K | Hold |
10
| – | – | ﹤0.01% | 359 |
|
|
2018
Q2 | $2K | Hold |
10
| – | – | ﹤0.01% | 387 |
|
|
2018
Q1 | $2K | Hold |
10
| – | – | ﹤0.01% | 358 |
|
|
2017
Q4 | $1K | Hold |
10
| – | – | ﹤0.01% | 381 |
|
|
2017
Q3 | $2K | Hold |
10
| – | – | ﹤0.01% | 281 |
|
|
2017
Q2 | $1K | Buy |
+10
| New | +$1.2K | ﹤0.01% | 315 |
|
Other funds holding VRTX
VCM
VPM
C.M. Bidwell & Associates's VRTX Position: Q1 2026 in Review
C.M. Bidwell & Associates held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 10 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #336.
C.M. Bidwell & Associates first reported a position in VRTX in Q2 2017 and has held it in 36 quarters since. The position peaked at $642K in Q1 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- C.M. Bidwell & Associates held 10 shares of Vertex Pharmaceuticals worth $4.46K as of Q1 2026.
- C.M. Bidwell & Associates left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
- Vertex Pharmaceuticals made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #336 holding.
- C.M. Bidwell & Associates first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 36 quarters since.
- C.M. Bidwell & Associates's Vertex Pharmaceuticals position peaked at $642K in Q1 2020.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.